Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Cardiovascular Risks Associated with Gender and Aging
Rodgers, J. L., Jones, J., Bolleddu, S. I., Vanthenapalli, S., Rodgers, L. E., Shah, K., Karia, K., & Panguluri, S. K. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6020019 · Cited by 1,024
“While a majority of men show diminished testosterone levels with advanced age, these levels are still considered within the normal physiological range, without symptoms of androgen deficiency and hypogonadism [148].”
BackgroundSalonia, A., Bettocchi, C., Boeri, L., Capogrosso, P., Carvalho, J., Cilesiz, N. C., Cocci, A., Corona, G., Dimitropoulos, K., Gül, M., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.06.007 · Cited by 828
“5 ng/dl) are associated with hypogonadal symptoms (Table 1) [7,26,27].”
BackgroundUsing human genetics to understand the disease impacts of testosterone in men and women
The Endometrial Cancer Association Consortium, Ruth, K. S., Day, F. R., Tyrrell, J., Thompson, D. J., Wood, A. R., Mahajan, A., Beaumont, R. N., Wittemans, L., Martin, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0751-5 · Cited by 720
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Cardiovascular Safety of Testosterone-Replacement Therapy
Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215025 · Cited by 475
Self-citationCorona, G., Goulis, D. G., Huhtaniemi, I., Zitzmann, M., Toppari, J., Forti, G., Vanderschueren, D., & Wu, F. C. (2020) · Andrology · doi:10.1111/andr.12770 · Cited by 431
Self-citationWittert, G., Bracken, K., Robledo, K. P., Grossmann, M., Yeap, B. B., Handelsman, D. J., Stuckey, B., Conway, A., Inder, W., McLachlan, R., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30367-3 · Cited by 362
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
After another decade: LC–MS/MS became routine in clinical diagnostics
Seger, C., & Salzmann, L. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.03.004 · Cited by 301
Paediatric and adult-onset male hypogonadism
Salonia, A., Rastrelli, G., Hackett, G., Seminara, S. B., Huhtaniemi, I. T., Rey, R. A., Hellstrom, W. J. G., Palmert, M. R., Corona, G., Dohle, G. R., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0087-y · Cited by 286
Erectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 285
“ment and routine hormonal screening for male hypogonadism should be recommended in male patients with obesity with concomitant DM and ED.(31,106) Weight loss should be the first‐line therapeutic approach for improving erectile function in obese men with DM.”
BackgroundAmerican Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s004 · Cited by 285
Obesity: A critical risk factor in the COVID‐19 pandemic
Kwok, S., Adam, S., Ho, J. H., Iqbal, Z., Turkington, P., Razvi, S., Le Roux, C. W., Soran, H., & Syed, A. A. (2020) · Clinical Obesity · doi:10.1111/cob.12403 · Cited by 255
Osteoporosis in Men: A Review of an Underestimated Bone Condition
Rinonapoli, G., Ruggiero, C., Meccariello, L., Bisaccia, M., Ceccarini, P., & Caraffa, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042105 · Cited by 245
“Therefore, to avoid excessive bone loss, testosterone replacement therapy becomes essential and is particularly recommended in young adults [119,128].”
What triggers dye adsorption by metal organic frameworks? The current perspectives
Shahnawaz Khan, M., Khalid, M., & Shahid, M. (2020) · Materials Advances · doi:10.1039/d0ma00291g · Cited by 240
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s004 · Cited by 222
Vilaca, T., Eastell, R., & Schini, M. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00012-2 · Cited by 210
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Cusi, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s004 · Cited by 205
Zitzmann, M., Aksglaede, L., Corona, G., Isidori, A. M., Juul, A., T'Sjoen, G., Kliesch, S., D'Hauwers, K., Toppari, J., Słowikowska‐Hilczer, J., et al. (2021) · Andrology · doi:10.1111/andr.12909 · Cited by 206
Recent Advancement of Medical Patch for Transdermal Drug Delivery
Wong, W. F., Ang, K. P., Sethi, G., & Looi, C. Y. (2023) · Medicina · doi:10.3390/medicina59040778 · Cited by 199
Basics of androgen synthesis and action
Naamneh Elzenaty, R., du Toit, T., & Flück, C. E. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101665 · Cited by 199
Testosterone replacement therapy and cardiovascular risk
Gagliano-Jucá, T., & Basaria, S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0211-4 · Cited by 196
Current and investigational medications for the treatment of sarcopenia
Rolland, Y., Dray, C., Vellas, B., & Barreto, P. D. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155597 · Cited by 195
Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy
Longo, M., Bellastella, G., Maiorino, M. I., Meier, J. J., Esposito, K., & Giugliano, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00045 · Cited by 192
“As testosterone decline with advancing age, the assessment of its concentrations may be useful in case of signs and symptoms of overt hypogonadism to better evaluate the risk of fracture in this selected population (31, 32).”
BackgroundEAA clinical practice guidelines—gynecomastia evaluation and management
Kanakis, G. A., Nordkap, L., Bang, A. K., Calogero, A. E., Bártfai, G., Corona, G., Forti, G., Toppari, J., Goulis, D. G., & Jørgensen, N. (2019) · Andrology · doi:10.1111/andr.12636 · Cited by 191
Sarkar, M., Brady, C. W., Fleckenstein, J., Forde, K. A., Khungar, V., Molleston, J. P., Afshar, Y., & Terrault, N. A. (2021) · Hepatology · doi:10.1002/hep.31559 · Cited by 186
“(87) However, testosterone repletion may be associated with myocardial infarction or stroke,(88) and testosterone levels that prompt replacement vary by clinical symptoms.(89,90) Testosterone replacement therapy may be associated with transient elevations in liver enzymes that are usually self-limited.”
BackgroundAnabolic–androgenic steroids: How do they work and what are the risks?
Bond, P., Smit, D. L., & de Ronde, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1059473 · Cited by 184
European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
Pasquali, R., Casanueva, F., Haluzik, M., van Hulsteijn, L., Ledoux, S., Monteiro, M. P., Salvador, J., Santini, F., Toplak, H., & Dekkers, O. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0893 · Cited by 188
Walther, A., Breidenstein, J., & Miller, R. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.2734 · Cited by 176
Dhindsa, S., Zhang, N., McPhaul, M. J., Wu, Z., Ghoshal, A. K., Erlich, E. C., Mani, K., Randolph, G. J., Edwards, J. R., Mudd, P. A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.11398 · Cited by 164
Testosterone replacement therapy
Barbonetti, A., D’Andrea, S., & Francavilla, S. (2020) · Andrology · doi:10.1111/andr.12774 · Cited by 162
Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic
Pozzilli, P., & Lenzi, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154252 · Cited by 161
“It is well established that plasma testosterone concentration is reduced by age and comorbidities like obesity, diabetes and obstructive sleep apnea (OSA) [7], all comorbidities highly prevalent in COVID-19 patients [8].”
Hypogonadotropic Hypogonadism in Men With Diabesity
Dhindsa, S., Ghanim, H., Batra, M., & Dandona, P. (2018) · Diabetes Care · doi:10.2337/dc17-2510 · Cited by 158
Hormone Regulation in Testicular Development and Function
Li, L., Lin, W., Wang, Z., Huang, R., Xia, H., Li, Z., Deng, J., Ye, T., Huang, Y., & Yan, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115805 · Cited by 233
“Generally, repeated measurements of total testosterone concentration in the morning serum 9.7–10.4 nmol/L and free testosterone 0.17–0.31 nmol/L can be used as a reference value [184,185].”
MethodInfluentialWalker, R. F., Zakai, N. A., MacLehose, R. F., Cowan, L. T., Adam, T. J., Alonso, A., & Lutsey, P. L. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.5135 · Cited by 150
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 250
Insights and implications of sexual dimorphism in osteoporosis
Zhang, Y., Xie, N., Sun, X., Nice, E. C., Liou, Y., Huang, C., Zhu, H., & Shen, Z. (2024) · Bone Research · doi:10.1038/s41413-023-00306-4 · Cited by 184
“486 However, the effectiveness of testosterone in increasing BMD is less obvious than anti-osteoporosis medication.”
BackgroundIsidori, A. M., Aversa, A., Calogero, A. E., Ferlin, A., Francavilla, S., Lanfranco, F., Pivonello, R., Rochira, V., Corona, G., & Maggi, M. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01859-7 · Cited by 182
“Male hypogonadism can be due to a testicular dysfunction (primary hypogonadism), a pituitary/hypothalamic failure (secondary hypogonadism) or a combination of both (mixed hypogonadism) [13, 14, 16].”
BackgroundInfluentialSociety for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism
Jayasena, C. N., Anderson, R. A., Llahana, S., Barth, J. H., MacKenzie, F., Wilkes, S., Smith, N., Sooriakumaran, P., Minhas, S., Wu, F. C. W., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14633 · Cited by 147
“The objective of testosterone treatment is to reverse or prevent the symptoms and long‐term effects of MH and to maintain general well‐ being.(1) Optimised testosterone treatment can:”
BackgroundInfluentialSelf-citationAmerican Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc21-s004 · Cited by 174
Testosterone, mood, behaviour and quality of life
Zitzmann, M. (2020) · Andrology · doi:10.1111/andr.12867 · Cited by 176
Male Obesity-related Secondary Hypogonadism – Pathophysiology, Clinical Implications and Management
Fernandez, C. J., Department of Endocrinology & Metabolism, P. H., Chacko, E. C., Department of Endocrinology, J. G. H., Pappachan, J. M., & Department of Endocrinology & Metabolism, L. T. H. N. F. T. (2019) · European Endocrinology · doi:10.17925/ee.2019.15.2.83 · Cited by 145
“Management options Weight loss achieved using healthy lifestyle changes MOSH is a potentially reversible cause of HPT axis suppression and testosterone deficiency (functional hypogonadism) and hence can be managed with lifestyle measures to achieve significant weight loss, without the need for testosterone treatment.(…”
Backgroundvan Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Aging and sex hormones in males
Decaroli, M. C., & Rochira, V. (2017) · Virulence · doi:10.1080/21505594.2016.1259053 · Cited by 144
Aging and the Male Reproductive System
Kaufman, J.-M., Lapauw, B., Mahmoud, A., T’Sjoen, G., & Huhtaniemi, I. T. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00178 · Cited by 144
A Mechanistic and Pathophysiological Approach for Stroke Associated with Drugs of Abuse
Tsatsakis, A., Docea, A. O., Calina, D., Tsarouhas, K., Zamfira, L.-M., Mitrut, R., Sharifi-Rad, J., Kovatsi, L., Siokas, V., Dardiotis, E., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091295 · Cited by 142
“Furthermore, measuring serum testosterone concentrations and hematocrit is highly recommended [155].”
BackgroundReproductive Endocrinology of Nonalcoholic Fatty Liver Disease
Grossmann, M., Wierman, M. E., Angus, P., & Handelsman, D. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00158 · Cited by 142
Bhasin, S., Kerr, C. L., Oktay, K., & Racowsky, C. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00315 · Cited by 136
Self-citationThe Roles of Androgens in Humans: Biology, Metabolic Regulation and Health
Alemany, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911952 · Cited by 175
Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism
Genchi, V. A., Rossi, E., Lauriola, C., D’Oria, R., Palma, G., Borrelli, A., Caccioppoli, C., Giorgino, F., & Cignarelli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158194 · Cited by 175
Obesity and male hypogonadism: Tales of a vicious cycle
Carrageta, D. F., Oliveira, P. F., Alves, M. G., & Monteiro, M. P. (2019) · Obesity Reviews · doi:10.1111/obr.12863 · Cited by 138
“To ensure patient safety, testosterone treatment should only be considered if there are no unfavourable conditions for replacement therapy, such as the risk of prostate cancer or established cardiovascular disease, according to the most recent Endocrine Society Clinical Practice Guideline.127 Besides, in those men see…”
BackgroundMethodInfluentialLuo, S., Au Yeung, S. L., Zhao, J. V., Burgess, S., & Schooling, C. M. (2019) · BMJ · doi:10.1136/bmj.l476 · Cited by 124
Hypogonadism in Exercising Males: Dysfunction or Adaptive-Regulatory Adjustment?
Hackney, A. C. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00011 · Cited by 139
Chen, J., Lin, P., Tsai, Y.-R., Yang, Y.-C., & Kang, H. (2019) · Cells · doi:10.3390/cells8111318 · Cited by 140
“T replacement therapy (TRT) is recommended in hypogonadal men for the maintenance of sex characteristics and corrects androgen deficiency, although prostate cancer risk should be considered in different ages and populations [36].”
BackgroundInfluentialGroti, K., Žuran, I., Antonič, B., Foršnarič, L., & Pfeifer, M. (2018) · The Aging Male · doi:10.1080/13685538.2018.1468429 · Cited by 117
“According to the Endocrine Society Clinical Practice Guidelines [77], successful weight loss combined with optimization of glycemic control is the first-line”
MethodInfluentialAn Insight into the Sex Differences in COVID-19 Patients: What are the Possible Causes?
Dana, P. M., Sadoughi, F., Hallajzadeh, J., Asemi, Z., Mansournia, M. A., Yousefi, B., & Momen–Heravi, M. (2020) · Prehospital and Disaster Medicine · doi:10.1017/s1049023x20000837 · Cited by 127
Stoffers, I. E., de Vries, M. C., & Hannema, S. E. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.06.014 · Cited by 119
Assessment of free testosterone concentration
Keevil, B. G., & Adaway, J. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.008 · Cited by 111
Fleseriu, M., Christ‐Crain, M., Langlois, F., Gadelha, M. R., & Melmed, S. K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00342-8 · Cited by 141
Nordenström, A., Ahmed, S. F., van den Akker, E., Blair, J., Bonomi, M., Brachet, C., Broersen, L. H. A., Claahsen-van der Grinten, H. L., Dessens, A. B., Gawlik, A., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0073 · Cited by 108
Late‐onset hypogonadism: a concept comes of age
Nieschlag, E. (2020) · Andrology · doi:10.1111/andr.12719 · Cited by 104
Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis
van Hulsteijn, L. T., Pasquali, R., Casanueva, F., Haluzik, M., Ledoux, S., Monteiro, M. P., Salvador, J., Santini, F., Toplak, H., & Dekkers, O. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0666 · Cited by 103
Narinx, N., David, K., Walravens, J., Vermeersch, P., Claessens, F., Fiers, T., Lapauw, B., Antonio, L., & Vanderschueren, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04562-1 · Cited by 96
“Furthermore, in accordance with ES guidelines, added value of free T is also evident when SHBG levels are altered [7].”
BackgroundMethodInfluentialTreatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
Ide, V., Vanderschueren, D., & Antonio, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010021 · Cited by 101
“According to the Endocrine Society and European Academy of Andrology guidelines, only men with symptoms or signs of testosterone deficiency and repeatedly low serum testosterone concentrations on morning blood samples, taken in standardized conditions, should be diagnosed with hypogonadism [2,3].”
BackgroundMethodInfluentialEndocrinology of the Aging Prostate: Current Concepts
Cannarella, R., Condorelli, R. A., Barbagallo, F., Vignera, S. L., & Calogero, A. E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.554078 · Cited by 199
“T could cause the growth of subclinical cancers that are frequently hidden in the prostate of older men (35).”
BackgroundWiebe, D. J., Storey, E. P., Orchinik, J. E., Grady, M. F., Leddy, J. J., Willer, B. S., Haider, M. N., Mannix, R., Meehan, W. P., Vernau, B. T., et al. (2021) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000946 · Cited by 131
Characteristics and Attitudes of Men Using Anabolic Androgenic Steroids (AAS): A Survey of 2385 Men
Bonnecaze, A. K., O’Connor, T., & Aloi, J. (2020) · American Journal of Men s Health · doi:10.1177/1557988320966536 · Cited by 96
“AAS withdrawal syndrome has also been reported and is due to the sudden decline in androgen levels with resultant anabolic steroid-induced hypogonadism (ASIH) and neuropsychiatric effects (Bertozzi et al., 2019; Bhasin et al., 2018; Pope et al., 2014).”
BackgroundSex differences in vascular aging in response to testosterone
Moreau, K. L., Babcock, M. C., & Hildreth, K. L. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00294-8 · Cited by 107
“Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society Clinical Practice Guideline.”
BackgroundInfluentialFredericson, M., Kussman, A., Misra, M., Barrack, M. T., De Souza, M. J., Kraus, E., Koltun, K. J., Williams, N. I., Joy, E., & Nattiv, A. (2021) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000948 · Cited by 93
Late‐onset hypogonadism: metabolic impact
Grossmann, M., Ng Tang Fui, M., & Cheung, A. S. (2020) · Andrology · doi:10.1111/andr.12705 · Cited by 95
COVID-19 and the Endocrine System: A Comprehensive Review on the Theme
Lisco, G., Tullio, A. D., Stragapede, A., Solimando, A. G., Albanese, F., Capobianco, M., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., Vacca, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132920 · Cited by 109
“Additionally, T replacement therapy should be continued in patients with male hypogonadism, according to the general recommendations [251], and caution should be used in introducing therapies aiming to reduce T or increase estradiol serum levels in men with confirmed COVID-19 until specific clinical trials are carried…”
BackgroundHandelsman, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab001 · Cited by 110
Pencina, K. M., Travison, T. G., Cunningham, G. R., Lincoff, A. M., Nissen, S. E., Khera, M., Miller, M. G., Flevaris, P., Li, X., Wannemuehler, K. A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad484 · Cited by 107
Self-citationGrande, G., Barrachina, F., Soler‐Ventura, A., Jodar, M., Mancini, F., Marana, R., Chiloiro, S., Pontecorvi, A., Oliva, R., & Milardi, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.852661 · Cited by 122
“0 mUI/ ml, and (3) clinical symptoms of hypogonadism.”
BackgroundInfluentialKaur, H., & Werstuck, G. H. (2021) · CJC Open · doi:10.1016/j.cjco.2021.05.007 · Cited by 114
Bauer, J. M., Cruz-Jentoft, A. J., Fielding, R. A., Kanis, J. A., Reginster, J.-Y., Bruyère, O., Cesari, M., Chapurlat, R., Al-Daghri, N., Dennison, E., et al. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00561-w · Cited by 83
Madsen, M. C., van Dijk, D., Wiepjes, C. M., Conemans, E. B., Thijs, A., & den Heijer, M. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab089 · Cited by 108
“48 L/L is associated with a moderate-high risk of adverse outcome (33).”
BackgroundThe role of testosterone in male sexual function
Corona, G., & Maggi, M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09748-3 · Cited by 110
Treatment of Functional Hypogonadism Besides Pharmacological Substitution
Corona, G., Rastrelli, G., Morelli, A., Sarchielli, E., Cipriani, S., Vignozzi, L., & Maggi, M. (2020) · The World Journal of Men's Health · doi:10.5534/wjmh.190061 · Cited by 87
“According to the majority of Andrology Societies [6-9], and to the Endocrine Society [3], only TD men presenting typical symptoms can be categorized and treated as a true HG. LOH, also in its symptomatic form, is often associated with aging and its related comorbidities, including obesity, metabolic syndrome (MetS) an…”
BackgroundInfluentialSwerdloff, R. S., Wang, C., White, W. B., Kaminetsky, J. C., Gittelman, M., Longstreth, J. A., Dudley, R. E., & Danoff, T. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa238 · Cited by 92
“A cosyntropin [ACTH (1-23)] stimulation test was conducted on a subset of patients (N = 24 on oral TU and N = 8 on topical T).”
BackgroundMethodSelf-citationTestosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment
Gianatti, E., & Grossmann, M. (2019) · Diabetic Medicine · doi:10.1111/dme.13977 · Cited by 91
Bhasin, S., Lincoff, A. M., Basaria, S. S., Bauer, D. C., Boden, W. E., Cunningham, G. R., Davey, D. A., Dubcenco, E., Fukumoto, S., Garcia, M., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.11.016 · Cited by 91
Self-citationSleep, testosterone and cortisol balance, and ageing men
Liu, P. Y., & Reddy, R. T. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09755-4 · Cited by 80
“Until such data are available, expert opinion will appropriately continue to caution against the use testosterone therapy in men with untreated severe OSA [123].”
BackgroundTestosterone deficiency in non-cancer opioid-treated patients
Coluzzi, F., Billeci, D., Maggi, M., & Corona, G. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0964-3 · Cited by 91
Kharroubi, S. A., & Diab-El-Harake, M. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1029190 · Cited by 97
Sex hormones, obesity and type 2 diabetes: is there a link?
Gambineri, A., & Pelusi, C. (2018) · Endocrine Connections · doi:10.1530/ec-18-0450 · Cited by 92
Measuring testosterone in women and men
Kanakis, G., Tsametis, C. P., & Goulis, D. G. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.04.203 · Cited by 88
“2 nmol/L (264 ng/dL), corresponding to the normal range of a population of healthy non-obese European and American men aged 19 to 39 years [6,7].”
BackgroundInfluentialAndrogens During Infancy, Childhood, and Adolescence: Physiology and Use in Clinical Practice
Mason, K. A., Schoelwer, M. J., & Rogol, A. D. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa003 · Cited by 94
Testosterone Is a Contraceptive and Should Not Be Used in Men Who Desire Fertility
Patel, A. S., Leong, J. Y., Ramos, L., & Ramasamy, R. (2019) · The World Journal of Men's Health · doi:10.5534/wjmh.180036 · Cited by 80
“1Department of Urology, University of Miami Miller School of Medicine, Miami, FL, 2Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA Testosterone has a variety of functions and is commonly used in older men to treat symptoms of hypogonadism, such as decreased libido, decreased mood and erectile…”
BackgroundInfluentialMechanisms underlying the metabolic actions of testosterone in humans: A narrative review
Dandona, P., Dhindsa, S., Ghanim, H., & Saad, F. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14206 · Cited by 95
“This review is not intended to be a description of clinical data obtained on the aforementioned variables in trials of testosterone replacement: excellent reviews on that topic are available.(1,5) Instead, we have focused on detailing the mechanisms that underlie the metabolic aspects of testosterone therapy in humans.”
BackgroundInfluentialSubstance Abuse and Male Hypogonadism
Duca, Y., Aversa, A., Condorelli, R. A., Calogero, A. E., & Vignera, S. L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050732 · Cited by 94
“In this case, to calculate free testosterone starting from total testosterone, SHBG, and albumin values is preferable [1].”
BackgroundInfluentialBjørnebekk, A., Westlye, L. T., Walhovd, K. B., Jørstad, M. L., Sundseth, Ø., & Fjell, A. M. (2019) · Neuropsychology · doi:10.1037/neu0000537 · Cited by 86
Opioid-induced endocrinopathies
Fountas, A., Van Uum, S., & Karavitaki, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30254-2 · Cited by 77
Cinislioğlu, A. E., Cinislioğlu, N., Demirdöğen, Ş. O., Şam, E., Akkaş, F., Altay, M. S., Utlu, M., Şen, İ. A., Yildirim, F., Kartal, S., et al. (2021) · Andrology · doi:10.1111/andr.13081 · Cited by 77
How we treat endocrine complications of immune checkpoint inhibitors
Paschou, S. Α., Stefanaki, K., Ψαλτοπούλου, Θ., Liontos, M., Koutsoukos, K., Zagouri, F., Lambrinoudaki, I. V., & Dimopoulos, M. A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100011 · Cited by 81
“In postmenopausal women, FSH and LH are physiologically elevated and this should be always considered for this population when hypogonadotropic hypogonadism is suspected.(31) Hypogonadotropic hypogonadism is transient and this axis recovers spontaneously in most cases.”
BackgroundGuideline of guidelines: testosterone therapy for testosterone deficiency
Salter, C. A., & Mulhall, J. P. (2019) · British Journal of Urology · doi:10.1111/bju.14899 · Cited by 74
Testosterone Therapy: What We Have Learned From Trials
Corona, G., Torres, L. O., & Maggi, M. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.11.270 · Cited by 81
“In particular, although a hematocrit >54% is considered a well accepted indication for TRT withdrawal and phlebotomy, the standard level of hematocrit to be considered for starting TRT is conflicting.(6,7,84) Much evidence has documented that TRT can increase hematocrit through different mechanisms, including direct (…”
BackgroundYeap, B. B., Marriott, R. J., Dwivedi, G., Adams, R., Antonio, L., Ballantyne, C. M., Bauer, D. C., Bhasin, S., Biggs, M. L., Cawthon, P. M., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-2781 · Cited by 96
“Therefore, the combination of low testosterone and low SHBG concentrations seems to be benign, which is consistent with the concept that men with low SHBG may also have low circulating testosterone in the absence of androgen de fi ciency (5, 7).”
BackgroundResultInfluentialSelf-citationO’Reilly, M. W., Glisic, M., Kumarendran, B., Subramanian, A., Manolopoulos, K. N., Tahrani, A. A., Keerthy, D., Muka, T., Toulis, K. A., Hanif, W., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.13862 · Cited by 72
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.